Maravai LifeSciences Holdings, Inc.
MRVI
$3.08
-$0.21-6.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -28.34% | -30.47% | -19.95% | -11.76% | -10.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.34% | -30.47% | -19.95% | -11.76% | -10.30% |
| Cost of Revenue | -0.55% | 2.07% | 2.69% | -1.13% | 1.43% |
| Gross Profit | -67.05% | -68.32% | -46.69% | -25.28% | -22.75% |
| SG&A Expenses | -11.04% | -0.08% | 2.45% | 7.32% | 9.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.18% | 0.58% | 2.46% | 3.15% | 5.92% |
| Operating Income | -72.85% | -186.56% | -131.50% | -90.18% | -198.27% |
| Income Before Tax | 10.14% | -149.47% | -158.25% | -148.64% | -142.33% |
| Income Tax Expenses | -126.45% | -100.55% | -100.50% | -100.26% | -100.25% |
| Earnings from Continuing Operations | 11.12% | 33.91% | -105.32% | -81.45% | -87.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.88% | -5.90% | 366.19% | 343.30% | 493.28% |
| Net Income | 9.72% | 46.20% | -43.36% | -24.17% | -21.69% |
| EBIT | -72.85% | -186.56% | -131.50% | -90.18% | -198.27% |
| EBITDA | -205.02% | -13,419.57% | -3,135.03% | -920.10% | -252.96% |
| EPS Basic | 12.21% | 48.97% | -33.27% | -15.89% | -14.53% |
| Normalized Basic EPS | -83.72% | -100.56% | -85.03% | -86.96% | -87.55% |
| EPS Diluted | 12.21% | 48.97% | -33.14% | -15.77% | -14.40% |
| Normalized Diluted EPS | -83.72% | -100.56% | -85.03% | -86.96% | -87.55% |
| Average Basic Shares Outstanding | 4.69% | 5.96% | 7.29% | 6.51% | 4.52% |
| Average Diluted Shares Outstanding | 4.69% | 5.96% | 7.29% | 6.51% | 4.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |